Tumour site specific group (TSSG) - Haematology  Professional information site

Updates in August 2012: Lymphoma protocols: Updated: ABVD, Alemtuzumab + Dexamethasone, BEAM, Bendamustine-100 for CLL, Bendamustine-120 for NHL, Bendamustine-70-R for CLL, Bendamustine-90-R for NHL, Brentuximab vedotin, Chlorambucil, ChlVPP, CHOD, CHOP-21 standard, Cladribine, Doxorubicin for urgent use, GEM-P, Methotrexate (weekly), Ofatumumab, Ofatumumab + pulsed Demxamethasone, PMitCEBO, R-CODOX-M / R-IVAC, R-CP, R-CVP, R-GCVP, R-ICE priming, R-PMitCEBO, R-VP, Romidepsin, Temsirolimus. Myeloma protocols: Updated: Bendamustine, thalidomide and dexamethasone (BTD); Bisphosphonates in myeloma; Bortizomib (Velcade); Bortezomib (Velcade) weekly / cyclophosphamide / dexamethasone (VCD); Bortezomib, melphalan and prednisolone (VMP); CTD - full dose; CTDa - attenuated; Cyclophosphamide - oral; Dexamethasone - high dose; DTPACE; Intermediate dose melphalan with dexamethasone; Lenalidomide with dexamethasone; Lenalidomide, cyclophosphamide and weekly dexamethasone; Melphalan +/- prednisolone; Melphalan, prednisolone and thalidomide (MPT); Thalidomide +/- dexamethasone; Z-DEX.